Eli Lilly Lands First China Approval for Oral GLP-1 Weight-Loss Pill

Eli Lilly won Chinese regulatory clearance for orforglipron, its oral GLP-1 weight-loss drug, according to a Reuters report citing the country's medicine regulator. That makes Lilly the first drugmaker with an approved oral GLP-1 obesity treatment in China. The nod lands while Novo Nordisk, Pfizer and domestic player Innovent Biologics compete in a market still dominated by injectable products.

Novo Nordisk has already filed to bring an oral version of Wegovy to China, so Lilly's head start will be tested quickly. J.P. Morgan's head of China healthcare research estimates annual GLP-1 weight-management sales in China run at 3 billion to 4 billion yuan today and will reach 300 billion yuan, or roughly $45 billion, within five to seven years. Oral therapies are expected to lower access barriers and speed up market penetration.

Lilly's balance sheet gives it room to press the advantage. Fiscal 2025 revenue came in at about $65.2 billion, up 44.7% from the prior year, while net income hit roughly $20.6 billion against $10.6 billion in fiscal 2024, with a net margin near 31.7%. Zepbound and Mounjaro together drive 56% of total revenue, a concentration the China launch helps dilute.

The stock carries a premium: 40.5 times forward earnings and 15.6 times sales. On the risk side, rival oral products are working through regulators, clouding how long Lilly's first-mover edge holds, and a heavy manufacturing expansion could slow the growth trajectory if new facilities come online late. Further out, investors are watching retatrutide, Lilly's investigational triple-agonist, and its siRNA therapy targeting lipoprotein(a).